PI3K-PKB-mTOR hyperactivation in relation to nasopharyngeal carcinoma progression and prognosis
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
PI3K-PKB-mTOR hyperactivation in relation to nasopharyngeal carcinoma progression and prognosis
Authors
Keywords
-
Journal
JOURNAL OF CELLULAR BIOCHEMISTRY
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2018-12-24
DOI
10.1002/jcb.28303
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- PI3K/Akt/mTOR and Ras/Raf/MEK/ERK signaling pathways inhibitors as anticancer agents: Structural and pharmacological perspectives
- (2016) Vivek Asati et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Reduced expression of polymeric immunoglobulin receptor (pIgR) in nasopharyngeal carcinoma and its correlation with prognosis
- (2016) Xuanchang Qi et al. TUMOR BIOLOGY
- Gefitinib induces lung cancer cell autophagy and apoptosis via blockade of the PI3K/AKT/mTOR pathway
- (2016) ZHONG-QUAN ZHAO et al. Oncology Letters
- miR-3188 regulates nasopharyngeal carcinoma proliferation and chemosensitivity through a FOXO1-modulated positive feedback loop with mTOR–p-PI3K/AKT-c-JUN
- (2016) Mengyang Zhao et al. Nature Communications
- Clinical and biological significance of HAX-1 overexpression in nasopharyngeal carcinoma
- (2016) Bo You et al. Oncotarget
- Genetic variations in the PI3K-PTEN-AKT-mTOR pathway are associated with distant metastasis in nasopharyngeal carcinoma patients treated with intensity-modulated radiation therapy
- (2016) Qiaojuan Guo et al. Scientific Reports
- Alcohol drinking as an unfavorable prognostic factor for male patients with nasopharyngeal carcinoma
- (2016) Yu-Pei Chen et al. Scientific Reports
- CIP2A overexpression induces autoimmune response and enhances JNK signaling pathway in human lung cancer
- (2015) Bo Peng et al. BMC CANCER
- Post-trial obligations in the Declaration of Helsinki 2013: classification, reconstruction and interpretation
- (2015) Ignacio Mastroleo Developing World Bioethics
- Puquitinib mesylate (XC-302) induces autophagy via inhibiting the PI3K/AKT/mTOR signaling pathway in nasopharyngeal cancer cells
- (2015) KE-FENG WANG et al. INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
- A Review: Proteomics in Nasopharyngeal Carcinoma
- (2015) Ze-Tan Chen et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Downregulation of cancer stem cell properties via mTOR signaling pathway inhibition by rapamycin in nasopharyngeal carcinoma
- (2015) CHUNGUANG YANG et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Centipeda minima (Ebushicao) extract inhibits PI3K-Akt-mTOR signaling in nasopharyngeal carcinoma CNE-1 cells
- (2015) Yu-qing Guo et al. Chinese Medicine
- Abnormal Protein Glycosylation and Activated PI3K/Akt/mTOR Pathway: Role in Bladder Cancer Prognosis and Targeted Therapeutics
- (2015) Céu Costa et al. PLoS One
- PP242 suppresses cell proliferation, metastasis, and angiogenesis of gastric cancer through inhibition of the PI3K/AKT/mTOR pathway
- (2014) Xiaofang Xing et al. ANTI-CANCER DRUGS
- Five-Year Survival and Median Survival Time of Nasopharyngeal Carcinoma in Hospital Universiti Sains Malaysia
- (2014) Ab Hamid Siti-Azrin et al. Asian Pacific Journal of Cancer Prevention
- Dual PI3K/mTOR Inhibitors, GSK2126458 and PKI-587, Suppress Tumor Progression and Increase Radiosensitivity in Nasopharyngeal Carcinoma
- (2014) T. Liu et al. MOLECULAR CANCER THERAPEUTICS
- Ephrin type-A receptor 2 regulates sensitivity to paclitaxel in nasopharyngeal carcinoma via the phosphoinositide 3-kinase/Akt signalling pathway
- (2014) YUNYUN WANG et al. Molecular Medicine Reports
- Activation of the PI3K/mTOR/AKT Pathway and Survival in Solid Tumors: Systematic Review and Meta-Analysis
- (2014) Alberto Ocana et al. PLoS One
- Epigenetic Inactivation of Inositol polyphosphate 4-phosphatase B (INPP4B), a Regulator of PI3K/AKT Signaling Pathway in EBV-Associated Nasopharyngeal Carcinoma
- (2014) Jessie Wai-Fong Yuen et al. PLoS One
- Activation of Akt/mTOR Pathway Is Associated with Poor Prognosis of Nasopharyngeal Carcinoma
- (2014) Weiyuan Wang et al. PLoS One
- The role of microRNAs in nasopharyngeal carcinoma
- (2014) Gongjun Tan et al. TUMOR BIOLOGY
- PI3K/Akt/mTOR pathway inhibitors enhance radiosensitivity in radioresistant prostate cancer cells through inducing apoptosis, reducing autophagy, suppressing NHEJ and HR repair pathways
- (2014) L Chang et al. Cell Death & Disease
- Identification of Genetic and Non-genetic Risk Factors for Nasopharyngeal Carcinoma in a Southeast Asian Population
- (2013) Nikman Adli Nor Hashim et al. Asian Pacific Journal of Cancer Prevention
- The novel mTOR inhibitor CCI-779 (temsirolimus) induces antiproliferative effects through inhibition of mTOR in Bel-7402 liver cancer cells
- (2013) Shuyu Li et al. Cancer Cell International
- Recurrent nasopharyngeal carcinoma: a clinical dilemma and challenge
- (2013) Tao Xu et al. Current Oncology
- mTOR inhibitor RAD001 (everolimus) induces apoptotic, not autophagic cell death, in human nasopharyngeal carcinoma cells
- (2013) YUCHEN CAI et al. INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
- Developing Genetic Epidemiological Models to Predict Risk for Nasopharyngeal Carcinoma in High-Risk Population of China
- (2013) Hong-Lian Ruan et al. PLoS One
- Neoalbaconol induces energy depletion and multiple cell death in cancer cells by targeting PDK1-PI3-K/Akt signaling pathway
- (2013) Q Deng et al. Cell Death & Disease
- Headache as the Sole Symptom of Nasopharyngeal Carcinoma and Its Clinical Implications
- (2012) Yi-Lun Lee et al. TheScientificWorldJOURNAL
- Ridaforolimus (AP23573; MK-8669), a Potent mTOR Inhibitor, Has Broad Antitumor Activity and Can Be Optimally Administered Using Intermittent Dosing Regimens
- (2011) V. M. Rivera et al. MOLECULAR CANCER THERAPEUTICS
- PI3K/Akt/mTOR Pathway Inhibitors in Cancer: A Perspective on Clinical Progress
- (2010) P. Wu et al. CURRENT MEDICINAL CHEMISTRY
- A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer
- (2009) Robert J. Amato et al. CANCER
- Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy
- (2009) RuiRong Yuan et al. Journal of Hematology & Oncology
- Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/mTOR inhibitor prevents expansion of human BCR-ABL+ leukemia cells
- (2008) Michael G. Kharas et al. JOURNAL OF CLINICAL INVESTIGATION
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started